<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">34472111</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>12</Month>
        <Day>03</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>12</Month>
        <Day>14</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1346-8138</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>48</Volume>
            <Issue>12</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>Dec</Month>
            </PubDate>
          </JournalIssue>
          <Title>The Journal of dermatology</Title>
          <ISOAbbreviation>J Dermatol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Chronological evaluation of treatment effect for tinea unguium with efinaconazole: Possibility of an early estimation of treatment effects.</ArticleTitle>
        <Pagination>
          <StartPage>1923</StartPage>
          <EndPage>1925</EndPage>
          <MedlinePgn>1923-1925</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1111/1346-8138.16133</ELocationID>
        <Abstract>
          <AbstractText>The topical antifungal efinaconazole was applied to 27 nails (17 patients), and the treatment effects were monitored over a stipulated period (after 3, 6, and 12 months). Fourteen nails were observed for 18 months. Effects of the treatment were determined on the basis of the improvement rate of the turbidity ratio compared with that before treatment. After 12 months, five nails were cured and marked improvement was noted, whereas moderate and marked improvements were noted in 11 and six nails, respectively. The cured patients exhibited a significantly better improvement rate at 6 months (68.8%) than the other groups. Only 10.6% improvement was observed at the same point in time for the mild improvement group. Thus, in cases where the improvement rate after 6 months of treatment was 10% or less, it was judged that oral treatment should be considered. Furthermore, of the nails monitored for 18 months, those that exhibited further growth in improvement rates at 12 months was 51.6%, suggesting that an improvement rate of 50% at 12 months after starting treatment could be used as an indicator to determine switching to oral treatment.</AbstractText>
          <CopyrightInformation>© 2021 Japanese Dermatological Association.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Takenaka</LastName>
            <ForeName>Motoi</ForeName>
            <Initials>M</Initials>
            <Identifier Source="ORCID">0000-0002-7045-2518</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Dermatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Murota</LastName>
            <ForeName>Hiroyuki</ForeName>
            <Initials>H</Initials>
            <Identifier Source="ORCID">0000-0002-0450-1377</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Dermatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Nishimoto</LastName>
            <ForeName>Katsutarou</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Dermatology, Nagasaki Ekisaikai Hostipal, Nagasaki, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>09</Month>
          <Day>02</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>J Dermatol</MedlineTA>
        <NlmUniqueID>7600545</NlmUniqueID>
        <ISSNLinking>0385-2407</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000935">Antifungal Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D014230">Triazoles</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>J82SB7FXWB</RegistryNumber>
          <NameOfSubstance UI="C431707">efinaconazole</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000287" MajorTopicYN="N">Administration, Topical</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000935" MajorTopicYN="N">Antifungal Agents</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014009" MajorTopicYN="Y">Onychomycosis</DescriptorName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014230" MajorTopicYN="N">Triazoles</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">early estimation</Keyword>
        <Keyword MajorTopicYN="N">efinaconazole</Keyword>
        <Keyword MajorTopicYN="N">onychomycosis</Keyword>
        <Keyword MajorTopicYN="N">tinea unguium</Keyword>
        <Keyword MajorTopicYN="N">topical triazole antifungal</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="revised">
          <Year>2021</Year>
          <Month>7</Month>
          <Day>15</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>6</Month>
          <Day>16</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>8</Month>
          <Day>17</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>9</Month>
          <Day>3</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>15</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>9</Month>
          <Day>2</Day>
          <Hour>7</Hour>
          <Minute>9</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34472111</ArticleId>
        <ArticleId IdType="doi">10.1111/1346-8138.16133</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Title>REFERENCES</Title>
        <Reference>
          <Citation>Watanabe S, Harada T, Hiruma M, Iozumi K, Katoh T, Mochizuki T, et al. Epidemiological survey of foot diseases in Japan: Results of 30,000 foot checks by dermatologists. J Dermatol. 2010;37:397-406.</Citation>
        </Reference>
        <Reference>
          <Citation>Noguchi H, Matsumoto T, Hiruma M, Asao K, Hirose M, Fukushima S, et al. Topical efinaconazole: a promising therapeutic medication for tinea unguium. J Dermatol. 2018;45:1225-8.</Citation>
        </Reference>
        <Reference>
          <Citation>Iozumi K, Abe M, Ito Y, Uesugi T, Onoduka T, Katoh I, et al. Efficacy of long-term treatment with efinaconazole 105 solution in patients with onychomycosis, including severe cases; A multicenter, single-arm study. J Dermatol. 2019;46:641-51.</Citation>
        </Reference>
        <Reference>
          <Citation>Hiruma M, Matsushita A, Kobayashi M, Ogawa H. One-week pulse therapy with itraconazole (200 mg day-1) for onychomycosis. Evaluation of treatment results according to patient background. Mycoses. 2001;44:87-93.</Citation>
        </Reference>
        <Reference>
          <Citation>Elewski BE, Rich P, Pollak R, Pariser DM, Watanabe S, Senda H, et al. Efinaconazole 10% solution in the treatment of toenail onychomycosis: two phase 3 multicenter, randomized, double-blind studies. J Am Acad Dermatol. 2013;68:600-8.</Citation>
        </Reference>
        <Reference>
          <Citation>Watanabe S, Igarashi A, Katoh T, Matsuda T, Yamada K, Nishimoto K. Efficacy and safety of efinaconazole shown in Japanese patients with onychomycosis in the phase 3 global clinical trial. Nishinihon J Dermatol. 2015;77:256-64.</Citation>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
